product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb
catalog :
2243S
quantity :
100 ul
price :
274 USD
clonality :
monoclonal
host :
rabbit
antigen modification :
phosphorylated
clone name :
6B12
reactivity :
human
application :
western blot, immunohistochemistry, immunocytochemistry, immunohistochemistry - frozen section
more info or order :
Cell Signaling Technology product webpage
citations: 15
Published Application/Species/DilutionReference
  • western blot; human; fig 1
Meng Y, Zheng L, Yang Y, Wang H, Dong J, Wang C, et al. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Oncogenesis. 2016;5:e211 pubmed publisher
  • western blot; human; fig 1
  • immunocytochemistry; human; fig 1
Jeong J, VanHouten J, Dann P, Kim W, Sullivan C, Yu H, et al. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proc Natl Acad Sci U S A. 2016;113:E282-90 pubmed publisher
  • western blot; human; fig 4
Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine. 2015;2:396-405 pubmed
  • western blot; human
Wang J, Mikse O, Liao R, Li Y, Tan L, Jänne P, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34:2167-77 pubmed publisher
  • western blot; human; fig 3A
Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, et al. Molecular architecture of the ErbB2 extracellular domain homodimer. Oncotarget. 2015;6:1695-706 pubmed
  • western blot; human; fig 2
Brouxhon S, Kyrkanides S, Teng X, O'Banion M, Clarke R, Byers S, et al. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog. 2014;53:893-906 pubmed publisher
  • western blot; human
Hong Y, Kim J, Pectasides E, Fox C, Hong S, Ma Q, et al. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS ONE. 2014;9:e109440 pubmed publisher
  • western blot; human
Kugel C, Hartsough E, Davies M, Setiady Y, Aplin A. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014;74:4122-32 pubmed publisher
Suzuki M, Shiraishi K, Yoshida A, Shimada Y, Suzuki K, Asamura H, et al. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation. Lung Cancer. 2015;87:14-22 pubmed publisher
Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, et al. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol. 2014;21:S490-6 pubmed publisher
Minami T, Kijima T, Otani Y, Kohmo S, Takahashi R, Nagatomo I, et al. HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer. Mol Cancer Ther. 2012;11:830-41 pubmed publisher
Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs. 2012;30:1352-60 pubmed publisher
Weigelt B, Lo A, Park C, Gray J, Bissell M. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat. 2010;122:35-43 pubmed publisher
Frogne T, Laenkholm A, Lyng M, Henriksen K, Lykkesfeldt A. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009;11:R11 pubmed publisher
Paulson A, Linklater E, Berghuis B, App C, Oostendorp L, Paulson J, et al. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res. 2013;11:1112-21 pubmed publisher
product information
SKU :
2243S
Product-Name :
Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb
Size :
100 ul
Price-(USD) :
274 USD
Species-x-Reactivity :
H
Applications :
Immunohistochemistry (Frozen)
Product-Category :
RTK
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
185
Host :
Rabbit
Target :
HER2/ErbB2 (Tyr1221/Tyr1222) phosphate
Primary-Protein :
HER2
Alt-Names :
CD340,ERBB2,HER-2,HER-2/neu,HER2,MLN 19,MLN19,Metastatic lymph node gene 19 protein,NEU,NGL,Proto-oncogene Neu,Proto-oncogene c-ErbB-2,Receptor tyrosine-protein kinase erbB-2,TKR1,Tyrosine kinase-type cell surface receptor HER2,c-erb B2/neu protein,erbB-2,herstatin,neuroblastoma/glioblastoma derived oncogene homolog,p185erbB2,v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog),v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.